首页|Emerging therapeutics in the management of connective tissue disease. Part II: Dermatomyositis and scleroderma

Emerging therapeutics in the management of connective tissue disease. Part II: Dermatomyositis and scleroderma

扫码查看
原文链接
  • NSTL
  • Elsevier
? 2022 American Academy of Dermatology, Inc.The management of connective tissue diseases is dramatically evolving with the advent of biologics and novel oral systemic therapeutics. Despite involvement in the care of these complex patients, there is a knowledge gap in the field of dermatology regarding these emerging agents. The second article in this continuing medical education series discusses new and emerging therapeutics for dermatomyositis and scleroderma that target cells, intracellular signaling pathways, and cytokines.

clinical trialsclinically amyopathic dermatomyositiscurrent management dermatomyositisjuvenile dermatomyositissclerodermasystemic sclerosis

Kodumudi V.、Bibb L.A.、Adalsteinsson J.A.、Shahriari N.、Skudalski L.、Santiago S.、Grant-Kels J.M.、Lu J.

展开 >

Department of Dermatology University of Connecticut Health Center

Department of Dermatology Brigham and Women's Hospital Harvard Medical School

Geisinger Commonwealth School of Medicine

2022

10.1016/j.jaad.2021.12.068

Journal of the American Academy of Dermatology

Journal of the American Academy of Dermatology

ISTP
ISSN：0190-9622
年,卷(期)：2022.87(1)
  • 169